Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Patients with History of Lymphoma

In a patient with a history of lymphoma, take into consideration the risk of bone involvement, and the length of time the patient has been in remission before prescribing Forsteo.

Relevant Information from Summary of Product Characteristics

Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide (contraindication).1

Forsteo is contraindicated in patients with prior external beam or implant radiation therapy to the skeleton.1

Clinical Trial Experience

Patients with a history of carcinoma in the previous five years or with a current suspicion were excluded from participating in clinical trials with teriparatide. However, patients with excised superficial lesions of the skin and those with a history of carcinoma in situ of the cervix or uterus were allowed to participate.2

There was no apparent increase in the incidence of cancers among all study participants treated with teriparatide compared with placebo during clinical trials.2


1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: March 03, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question